Humanised antibodies to the epidermal growth factor receptor

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01) C07K 16/46 (2006.01) C07K 19/00 (2006.01) C12N 5/10 (2006.01) C12N 15/62 (2006.01) C12N 15/85 (2006.01)

Patent

CA 2409361

The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer.

Cette invention a trait à une forme humanisée de l'anticorps 340, que l'on peut obtenir à partir d'une lignée cellulaire déposé par l'ECACC sous le numéro d'ordre 97021428. Ces anticorps se sont avérés être dotés d'une capacité accrue à tuer des cellules en comparaison de celle de l'anticorps murin 340. L'invention concerne également des acides nucléiques codant ces anticorps ainsi que l'utilisation qui est faite de ces anticorps en médecine, notamment pour traiter le cancer.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Humanised antibodies to the epidermal growth factor receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanised antibodies to the epidermal growth factor receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanised antibodies to the epidermal growth factor receptor will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1800871

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.